LA ART: System Considerations
Implementing Long-Acting Cabotegravir Plus Rilpivirine for HIV Treatment: System-Level Considerations

Released: August 02, 2022

Expiration: August 01, 2023

Yvonne Gilleece
Yvonne Gilleece, MB BCh, BAO, FRCP
Cristina Mussini
Cristina Mussini, MD
Babafemi Taiwo
Babafemi Taiwo, MBBS
Darrell H S Tan
Darrell H S Tan, MD, FRCPC, PhD

Activity

Progress
1
Course Completed

In this episode, an international expert panel shares their thoughts on key considerations at the operational level for incorporating long-acting injectable antiretroviral therapy into the HIV treatment armamentarium. Topics include the duration of injection appointments in real-world settings, managing additional patient volume/workload (particularly the key role of nurses), and preventing and addressing planned and unplanned missed doses. Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including:

  • Key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience
  • Long-acting HIV pre-exposure prophylaxis
  • What is still needed in long-acting HIV care to further address patient needs and inequities across subgroups